Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. - Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; et al. (International journal of cancer, 2014)